Wall Street brokerages expect that Redhill Biopharma Ltd. (NASDAQ:RDHL) will report earnings of ($0.76) per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Redhill Biopharma’s earnings, with the highest EPS estimate coming in at ($0.71) and the lowest estimate coming in at ($0.80). Redhill Biopharma reported earnings of ($0.70) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 8.6%. The company is expected to report its next quarterly earnings results on Monday, November 13th.

According to Zacks, analysts expect that Redhill Biopharma will report full-year earnings of ($2.64) per share for the current year, with EPS estimates ranging from ($2.70) to ($2.58). For the next financial year, analysts anticipate that the company will post earnings of ($2.28) per share, with EPS estimates ranging from ($2.50) to ($2.05). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Redhill Biopharma.

Redhill Biopharma (NASDAQ:RDHL) last posted its quarterly earnings data on Tuesday, July 25th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). The company had revenue of $0.48 million for the quarter, compared to the consensus estimate of $0.34 million.

RDHL has been the topic of several research reports. Zacks Investment Research downgraded shares of Redhill Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, July 29th. Roth Capital set a $27.00 price target on shares of Redhill Biopharma and gave the stock a “buy” rating in a report on Monday, July 31st. FBR & Co reiterated a “buy” rating on shares of Redhill Biopharma in a report on Friday, June 16th. HC Wainwright set a $33.00 price target on shares of Redhill Biopharma and gave the stock a “buy” rating in a report on Thursday, June 15th. Finally, UBS AG initiated coverage on shares of Redhill Biopharma in a report on Wednesday, September 13th. They issued a “reduce” rating on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $23.69.

A number of institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its position in Redhill Biopharma by 144.1% in the 1st quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock worth $595,000 after purchasing an additional 36,600 shares in the last quarter. D.A. Davidson & CO. boosted its position in Redhill Biopharma by 10.0% in the 2nd quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock worth $379,000 after purchasing an additional 4,000 shares in the last quarter. Jane Street Group LLC purchased a new stake in Redhill Biopharma in the 1st quarter worth approximately $276,000. Family Management Corp boosted its position in Redhill Biopharma by 51.5% in the 2nd quarter. Family Management Corp now owns 25,750 shares of the biotechnology company’s stock worth $222,000 after purchasing an additional 8,750 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its position in Redhill Biopharma by 10.8% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 25,569 shares of the biotechnology company’s stock worth $220,000 after purchasing an additional 2,500 shares in the last quarter. Institutional investors and hedge funds own 10.99% of the company’s stock.

Redhill Biopharma (NASDAQ:RDHL) traded up 7.56% during trading on Thursday, hitting $10.81. 345,796 shares of the company were exchanged. The firm’s 50 day moving average price is $8.65 and its 200-day moving average price is $9.37. Redhill Biopharma has a 1-year low of $8.16 and a 1-year high of $14.74. The stock’s market capitalization is $185.74 million.

TRADEMARK VIOLATION WARNING: This article was published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/zacks-analysts-expect-redhill-biopharma-ltd-rdhl-to-post-0-76-eps/1601617.html.

About Redhill Biopharma

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Get a free copy of the Zacks research report on Redhill Biopharma (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Redhill Biopharma (NASDAQ:RDHL)

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.